Three trials are focused on analyzing [68Ga]Ga-DOTA-SSTR diagnostic accuracy: (1) compared to MRI for meningiomas [81]; (2) for distinguishing normal pituitary tissue versus pituitary tumors [80]; (3) for measuring post-radiation tumor response [82]; and/or (4) for correlating tracer uptake to SSTR2 expression and other tumor molecular patterns [80,81,82]. The gene discussed is SSTR2; the disease is meningioma.